El maven

Manufactured by Agilent Technologies

El-MAVEN is a software application designed for the analysis of metabolomics data. It provides tools for peak picking, peak detection, and data visualization to aid in the identification and quantification of metabolites from mass spectrometry data.

Automatically generated - may contain errors

Lab products found in correlation

Qualitative analysis b 07, by Agilent Technologies (2 mentions) Agilent 6520 quadrupole time of flight mass spectrometer, by Agilent Technologies (1 mentions) 1290 liquid chromatography system, by Agilent Technologies (1 mentions) 6520 quadrupole time of flight mass spectrometer, by Agilent Technologies (1 mentions)

2 protocols using el maven

Metabolomics profiling of biological samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Analyses on Agilent 1290 liquid chromatography system coupled to Agilent 6520 quadrupole time-of- flight mass spectrometer as previously described [29 (link)]. The mass spectrometer, equipped with a dual- electrospray ionization source, was run in negative ion and then positive ion mode. The scan range was 50–1600 m/z. Source settings; drying gas flow rate: 11 L/min; nebulizer: 40 pounds per square inch gauge; gas temperature: 350 °C; capillary voltage: 3000 V (neg), 2500 V (pos). Metabolites were identified using MS/MS, with fragments compared against Agilent Metlin Metabolomics Database and Library. Liquid chromatography–mass spectrometry data were analyzed using Agilent Qualitative Analysis B.07.00, El-MAVEN (Elucidata), and Metabolomic Analysis and Visualization ENgine (MAVEN). Five biological replicates completed in each treatment group.

Parkhurst A., Wang S.Z., Findlay T.R., Malebranche K.J., Odabas A., Alt J., Maxwell M.J., Kaur H., Peer C.J., Figg W.D., Warren K.E., Slusher B.S., Eberhart C.G., Raabe E.H, & Rubens J.A. (2022). Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors. Cell Death & Disease, 13(4), 410.

+ Open protocol

+ Expand

Stable Isotope Tracing of Metabolites

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Stable isotope experiments were completed after cells were treated 24 hours with DON and incubated 2 hours with 4mM glutamine (¹³C₅, ¹⁵N₂, 99% purity) from Cambridge Isotope (Cat#: CNLM-1275-H-0.5). Cell samples were washed with ice-cold PBS, pelleted, and metabolites extracted with chilled 80% HPLC grade methanol (MeOH) as previously described (30 (link)). Analyses were completed on an Agilent 1290 liquid chromatography system coupled to an Agilent 6520 quadrupole time of flight mass spectrometer. The mass spectrometer, equipped with a dual electrospray ionization source, was run in negative ion and then positive ion mode. The scan range was 50–1600 m/z. The source settings consisted of: drying gas flow rate: 11 L/min; nebulizer: 40 pounds per square inch gauge; gas temp: 350ºC; capillary voltage: 3000 V (neg), 2500 V (pos). Metabolite identification was determined using MS/MS, with fragments compared against the Agilent Metlin Metabolomics Database and Library.
Liquid chromatography-mass spectrometry data were analyzed using Agilent Qualitative Analysis B.07.00, El-MAVEN (Elucidata), and Metabolomic Analysis and Visualization ENgine (MAVEN) as previously described (31 (link)).

Wang S.Z., Poore B., Alt J., Price A., Allen S.J., Hanaford A.R., Kaur H., Orr B.A., Slusher B.S., Eberhart C.G., Raabe E.H, & Rubens J.A. (2019). Unbiased metabolic profiling predicts sensitivity of high MYC-expressing atypical teratoid/rhabdoid tumors to glutamine inhibition with 6-diazo-5-oxo-L-norleucine. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(19), 5925-5936.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!